Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration
Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 21163-21185
DOI: 10.1021/acs.jmedchem.4c01938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.11.2024. Verfasst von Jean-Baptiste Langlois und 32 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Biomedical Research, Postfach, CH-4002 Basel, Switzerland. Hauptthemen laut MEDLINE: MAP Kinase Kinase Kinases, Osteoarthritis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Osteoarthritis (OA) is a chronic and degenerative joint disease affecting more than 500 million patients worldwide with no disease-modifying treatment approved to date. Several publications report on the transforming growth factor β-activated kinase 1 (TAK1) as a potential molecular target for OA, with complementary anti-catabolic and anti-inflammatory effects. We report herein on the development of TAK1 inhibitors with physicochemical properties suitable for intra-articular injection, with the aim to achieve high drug concentration at the affected joint, while avoiding severe toxicity associated with systemic inhibition. More specifically, reducing solubility by increasing crystallinity, while maintaining moderate lipophilicity proved to be a good compromise to ensure high and sustained free drug exposures in the joint. Furthermore, structure-based design allowed for an improvement of selectivity versus interleukin-1 receptor-associated kinases 1 and 4 (IRAK1/4). Finally, TAK-756 was discovered as a potent TAK1 inhibitor with good selectivity versus IRAK1/4 as well as excellent intra-articular pharmacokinetic properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novartis Biomedical Research, Postfach, CH-4002 Basel, Switzerland.
- Proteros Biostructures GmbH, Bunsenstrasse 7a, D-82152 Planegg-Martinsried, Germany.
ORCID-Profile: Jean-Baptiste Langlois, Stephane Rodde
Zitieren
APA
Langlois, J. B., Brenneisen, S., Rodde, S., Vangrevelinghe, E., Rose, G., Lerch, P., Sorge, M., Ullrich, T., Patora-Komisarska, K., Quancard, J., Larger, P., Gianola, L., Textor, C., Chenal, G., Rubic-Schneider, T., Simkova, K., Masmanidou, O., Scheufler, C., Lammens, A., …, & Minetti, G. C. (2024). Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration. Journal of Medicinal Chemistry, 67(23), 21163-21185. https://doi.org/10.1021/acs.jmedchem.4c01938
Vancouver
Langlois JB, Brenneisen S, Rodde S, Vangrevelinghe E, Rose G, Lerch P, et al. Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration. Journal of Medicinal Chemistry. 2024;67(23):21163-21185. doi:10.1021/acs.jmedchem.4c01938
BibTeX
@article{Langlois2024,
author = {Langlois, Jean-Baptiste and Brenneisen, Silke and Rodde, Stephane and Vangrevelinghe, Eric and Rose, Geoffroy and Lerch, Patrick and Sorge, Mickael and Ullrich, Thomas and Patora-Komisarska, Krystyna and Quancard, Jean and Larger, Patrice and Gianola, Lucas and Textor, Claudia and Chenal, Gaelle and Rubic-Schneider, Tina and Simkova, Katerina and Masmanidou, Olga and Scheufler, Clemens and Lammens, Alfred and Bouzan, Anais and Demirci, Sabrina and Flotte, Ludivine and Rivet, Helene and Hartmann, Lilian and Guezel, Danyel and Flueckiger, Manuela and Schilb, Alain and Schuepbach, Edi and Kettle, Rachel and Jacobi, Carsten and Pearson, David and Richards, Peter J and Minetti, Giulia C},
title = {Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {23},
pages = {21163--21185},
doi = {10.1021/acs.jmedchem.4c01938}
}
EUVIMED